as on September 16, 2025 at 1:29 am IST
Day's Low
Day's High
0.12%
Downside
0.12%
Upside
52 Week's Low
52 Week's High
58.72%
Downside
87.33%
Upside
Check Y-mabs Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$390.3M
EPS (TTM)
-0.8044
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-25.39
Industry PE ratio
-3.8535542168674697
P/B Ratio
0PEG Ratio
0EBITDA
-17.8M
Revenue (TTM)
85.4M
Profit Margin
-26.03%
Return On Equity TTM
8353100.00%
Track how Y-mabs Therapeutics Inc. P/E has moved over time to understand its valuation trends.
Y-mabs Therapeutics Inc. in the last 5 years
Lowest (0.00x)
September 15, 2025
Today (-25.39x)
September 15, 2025
Industry (-3.85x)
September 15, 2025
Highest (0.00x)
September 15, 2025
Today’s Price to Earnings Ratio: -25.39x
Compare market cap, revenue, PE, and other key metrics of Y-mabs Therapeutics Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $390.3M | -78.18% | -25.39 | -26.03% | |
BUY | $61.1B | 256.98% | -505.15 | -12.96% | |
NA | $38.7B | NA | NA | -3.89% | |
BUY | $101.1B | 47.85% | 28.07 | 31.86% | |
BUY | $59.4B | -3.43% | 14.11 | 31.37% |
The Y-mabs Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Y-mabs Therapeutics Inc. investment value today
Current value as on today
₹67,576
Returns
Returns from Y-mabs Therapeutics Inc. Stock
Dollar Returns*
₹4,985 (+4.99%)
Based on 13 analysts
76.92%
Buy
15.38%
Hold
7.69%
Sell
Based on 13 analysts, 76.92% of analysts recommend a 'BUY' rating for Y-mabs Therapeutics Inc.. Average target price of $8.6
Get share price movements and forecasts by analysts on Y-mabs Therapeutics Inc..
Target Price
$8.6
Current Price
$8.6
Analyzed by
13 Analysts
Target
$8.60
Y-mabs Therapeutics Inc. target price $8.6, a slight upside of 0% compared to current price of $8.6. According to 13 analysts rating.
Search interest for Y-mabs Therapeutics Inc. Stock has decreased by -91% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Netprofit is up for the last 5 quarters, -9.24M → -3.23M (in $), with an average increase of 31.6% per quarter
Price Rise
In the last 3 months, YMAB stock has moved up by 74.3%
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 157.7%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 70.6% return, outperforming this stock by 104.4%
Revenue Fall
Revenue is down for the last 3 quarters, 26.49M → 19.52M (in $), with an average decrease of 13.9% per quarter
Organisation | Y-mabs Therapeutics Inc. |
Headquarters | 202 Carnegie Center, Princeton, NJ, United States, 08540 |
Industry | Health Technology |
CEO | Mr. Michael Rossi |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Ms. Natalie Tucker | Senior VP & Radiopharmaceutical Business Unit Head |
Mr. Michael Rossi | CEO, President & Director |
Mr. Thomas Gad | Founder, Chief Business Officer & Vice Chairman |
Mr. Joris Wiel Jan Wilms | Senior VP & COO |
Dr. Torben Lund-Hansen M.Sc., Ph.D. | Senior VP & CTO |
Mr. John W. LaRocca Esq. | Senior VP, General Counsel, Secretary & Chief Legal Officer |
Mr. Peter P. Pfreundschuh CPA | Executive VP, CFO & Treasurer |
Ms. Courtney Dugan | VP & Head of Investor Relations |
Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Development Officer & Chief Medical Officer |
Mr. Doug Gentilcore | Senior VP & Head of DANYELZA Business Unit |
Y-mabs Therapeutics Inc. share price today is $8.6 as on at the close of the market. Y-mabs Therapeutics Inc. share today touched a day high of $8.61 and a low of $8.59.
Y-mabs Therapeutics Inc. share touched a 52 week high of $16.11 on and a 52 week low of $3.55 on . Y-mabs Therapeutics Inc. stock price today i.e. is closed at $8.6,which is 46.62% down from its 52 week high and 142.25% up from its 52 week low.
Y-mabs Therapeutics Inc. market capitalisation is $0.00T as on .
Indian investors can start investing in Y-mabs Therapeutics Inc. (YMAB) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Y-mabs Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Y-mabs Therapeutics Inc. share’s latest price of $8.6 as on September 16, 2025 at 1:29 am IST, you will get 1.1628 shares of Y-mabs Therapeutics Inc.. Learn more about
fractional shares .
Y-mabs Therapeutics Inc. stock has given -78.18% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?